Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib

Overview

Journal J Oncol

Specialty Oncology

Date 2022 May 13

PMID 35548853

Authors

Caihong Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effects of Curcumol on invasion, migration and epithelial-mesenchymal transformation of IGROV-1 and OVCAR-3 cells in ovarian cancer and its potential mechanism. Meanwhile, the effect of Curcumol on the antitumor activity of Niraparib was analyzed.

Methods: Cell Counting Kit 8 (CCK-8) was used to detect the effects of Curcumol on the activity of IGROV-1 and OVCAR 3 cells. In vitro invasion assay (Transwell) was used to test the invasiveness of cells. Cell migration was detected by scratch assay. The inhibitory effect of Curcumol on PAX8 was detected by QRT-PCR. To evaluate the antitumor effect of Curcumol in subcutaneous tumor-bearing animal model.

Results: Knockdown of PAX8 could inhibit the proliferation, invasion and migration of ovarian cancer cells. After Curcumol treated IGROV-1 and OVCAR-3 cells, the cell proliferation ability was decreased, the number of invasive cells was significantly reduced, and the scratch closure rate was significantly reduced, in a dose-dependent manner. Mechanism studies showed that Curcumol increased the antitumor activity of Niraparib by inhibiting PAX8.

Conclusion: Curcumol can inhibit the invasion, migration and epithelial-mesenchymal transformation of IGROV-1 and OVCAR-3 cells in ovarian cancer, and its mechanism is related to the targeted inhibition of PAX8. Curcumol also increased the sensitivity of Niraparib chemotherapy by inhibiting PAX8.

Citing Articles

Curcumol: a review of its pharmacology, pharmacokinetics, drug delivery systems, structure-activity relationships, and potential applications.

Zhai S, Wang R, Wang J, Xu X, Niu L, Guo M Inflammopharmacology. 2024; 32(3):1659-1704.

PMID: 38520574 DOI: 10.1007/s10787-024-01447-6.

Pharmacokinetics, tissue distribution, and plasma protein binding rate of curcumol in rats using liquid chromatography tandem mass spectrometry.

Yang Z, Sun Q, Wang S, Tang B, Yuan C, Wu Y Front Pharmacol. 2022; 13:1036732.

PMID: 36532730 PMC: 9748077. DOI: 10.3389/fphar.2022.1036732.

References

Wang J, Li X, Bai Z, Chi B, Wei Y, Chen X . Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway. J Ethnopharmacol. 2017; 210:1-9. DOI: 10.1016/j.jep.2017.06.037. View

Sun M, Ye Y, Xiao L, Duan X, Zhang Y, Zhang H . Anticancer effects of ginsenoside Rg3 (Review). Int J Mol Med. 2017; 39(3):507-518. DOI: 10.3892/ijmm.2017.2857. View

Bleu M, Mermet-Meillon F, Apfel V, Barys L, Holzer L, Bachmann Salvy M . PAX8 and MECOM are interaction partners driving ovarian cancer. Nat Commun. 2021; 12(1):2442. PMC: 8076227. DOI: 10.1038/s41467-021-22708-w. View

Kroll T, Sarraf P, Pecciarini L, Chen C, Mueller E, Spiegelman B . PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483):1357-60. DOI: 10.1126/science.289.5483.1357. View

Ren S, Zhang H, Mu Y, Sun M, Liu P . Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med. 2013; 33(3):413-6. DOI: 10.1016/s0254-6272(13)60189-2. View

Soriano A, de Cristofaro T, Di Palma T, Dotolo S, Gokulnath P, Izzo A . PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3. Cancer Cell Int. 2019; 19:303. PMC: 6865034. DOI: 10.1186/s12935-019-1022-8. View

Elias K, Emori M, Westerling T, Long H, Budina-Kolomets A, Li F . Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight. 2016; 1(13). PMC: 5017158. DOI: 10.1172/jci.insight.87988. View

Huang X, Qian J, Li L, Zhang X, Wei G, Lv J . Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/AKT pathway. Drug Dev Res. 2020; 81(8):1019-1025. DOI: 10.1002/ddr.21719. View

Yang X, Iyer A, Singh A, Choy E, Hornicek F, Amiji M . MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep. 2015; 5:8509. PMC: 4330541. DOI: 10.1038/srep08509. View

10.

Wei W, Rasul A, Sadiqa A, Sarfraz I, Hussain G, Nageen B . Curcumol: From Plant Roots to Cancer Roots. Int J Biol Sci. 2019; 15(8):1600-1609. PMC: 6643219. DOI: 10.7150/ijbs.34716. View

11.

Guillemette S, Serra R, Peng M, Hayes J, Konstantinopoulos P, Green M . Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev. 2015; 29(5):489-94. PMC: 4358401. DOI: 10.1101/gad.256214.114. View

12.

Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A . Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett. 2010; 31(3):375-83. View

13.

Xiao T, Zhong W, Zhao J, Qian B, Liu H, Chen S . Polyphyllin I suppresses the formation of vasculogenic mimicry via Twist1/VE-cadherin pathway. Cell Death Dis. 2018; 9(9):906. PMC: 6125388. DOI: 10.1038/s41419-018-0902-5. View

14.

Chi N, Epstein J . Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2001; 18(1):41-7. DOI: 10.1016/s0168-9525(01)02594-x. View

15.

Zhang J, Su G, Tang Z, Wang L, Fu W, Zhao S . Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3. Front Physiol. 2018; 9:234. PMC: 5870041. DOI: 10.3389/fphys.2018.00234. View

16.

Wang H, Zhong W, Zhao J, Zhang H, Zhang Q, Liang Y . Oleanolic Acid Inhibits Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization. Mol Cancer Ther. 2018; 18(1):62-74. DOI: 10.1158/1535-7163.MCT-18-0448. View

17.

Lang D, Powell S, Plummer R, Young K, Ruggeri B . PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2006; 73(1):1-14. DOI: 10.1016/j.bcp.2006.06.024. View

18.

Ning L, Ma H, Jiang Z, Chen L, Li L, Chen Q . Curcumol Suppresses Breast Cancer Cell Metastasis by Inhibiting MMP-9 Via JNK1/2 and Akt-Dependent NF-κB Signaling Pathways. Integr Cancer Ther. 2016; 15(2):216-25. PMC: 5736062. DOI: 10.1177/1534735416642865. View

19.

Adler E, Corona R, Lee J, Rodriguez-Malave N, Mhawech-Fauceglia P, Sowter H . The PAX8 cistrome in epithelial ovarian cancer. Oncotarget. 2018; 8(65):108316-108332. PMC: 5752447. DOI: 10.18632/oncotarget.22718. View

20.

Li C, Huang C, Ko C, Fang S, Ou-Yang F, Pan M . Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance Inhibition of Skp2-mediated Transcriptional Addiction. Anticancer Res. 2020; 40(10):5529-5538. DOI: 10.21873/anticanres.14565. View